Skip to content

RetinAI partners with Boehringer Ingelheim to improve retinal disease treatment

Life sciences

26 April 2023

Bern-based RetinAI Medical, a pioneer in clinical and imaging data management software and advanced analytics using AI for ophthalmology, has joined forces with Boehringer Ingelheim to improve patient outcomes in geographic atrophy (GA).

Geographic atrophy is an advanced form of age-related macular degeneration (AMD) and a leading cause of complete vision loss, affecting an estimated 5 million people worldwide. With the prevalence of GA expected to rise as the global population ages, the need for innovative treatments and diagnostic tools is more urgent than ever.

RetinAI, established in early 2017 in Bern, is a trailblazer in the development of software solutions that leverage advanced machine learning and computer vision to accelerate clinical, research, and pharmaceutical workflows in ophthalmology. The start-up’s Discovery platform, which has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE-mark certification, enables healthcare professionals to collect, organize, and analyze eye health data for faster, more informed decision-making.

A strategic collaboration for retinal disease treatment

RetinAI has entered into a strategic collaboration with Boehringer Ingelheim, a leading developer of innovative, more precise treatments and digital technologies in retinal diseases. Under the agreement, RetinAI will test its AI tools by analyzing Boehringer Ingelheim’s imaging datasets from clinical studies and real-world evidence. The aim is to identify novel biomarkers and predictors of disease progression that could accelerate the development of urgently needed treatments.

By integrating advanced digital technologies and AI, this partnership could enable earlier and more precise diagnoses, supporting Boehringer Ingelheim’s vision of preventing vision loss and blindness caused by retinal diseases. In return for access to its services and products, RetinAI will receive compensation from Boehringer Ingelheim.

Carlos Ciller, CEO of RetinAI, expressed optimism about the collaboration, stating, “Our Discovery platform and novel AI tools in GA accelerate research and provide robust disease insights. We are confident that this collaboration with Boehringer Ingelheim can pave the way to novel treatments that are better tailored to a patient’s disease, transforming the lives of people living with retinal diseases.”